Literature DB >> 30636572

Identifying Hypoperfusion in Moyamoya Disease With Arterial Spin Labeling and an [15O]-Water Positron Emission Tomography/Magnetic Resonance Imaging Normative Database.

Audrey P Fan1, Mohammad M Khalighi2, Jia Guo1,3, Yosuke Ishii1,4, Jarrett Rosenberg1, Mirwais Wardak1, Jun Hyung Park1, Bin Shen1, Dawn Holley1, Harsh Gandhi1, Tom Haywood1, Prachi Singh1, Gary K Steinberg5, Frederick T Chin1, Greg Zaharchuk1.   

Abstract

Background and Purpose- Noninvasive imaging of brain perfusion has the potential to elucidate pathophysiological mechanisms underlying Moyamoya disease and enable clinical imaging of cerebral blood flow (CBF) to select revascularization therapies for patients. We used hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) technology to characterize the distribution of hypoperfusion in Moyamoya disease and its relationship to vessel stenosis severity, through comparisons with a normative perfusion database of healthy controls. Methods- To image CBF, we acquired [15O]-water PET as a reference and simultaneously acquired arterial spin labeling (ASL) MRI scans in 20 Moyamoya patients and 15 age-matched, healthy controls on a PET/MRI scanner. The ASL MRI scans included a standard single-delay ASL scan with postlabel delay of 2.0 s and a multidelay scan with 5 postlabel delays (0.7-3.0s) to estimate and account for arterial transit time in CBF quantification. The percent volume of hypoperfusion in patients (determined as the fifth percentile of CBF values in the healthy control database) was the outcome measure in a logistic regression model that included stenosis grade and location. Results- Logistic regression showed that anterior ( P<0.0001) and middle cerebral artery territory regions ( P=0.003) in Moyamoya patients were susceptible to hypoperfusion, whereas posterior regions were not. Cortical regions supplied by arteries with stenosis on MR angiography showed more hypoperfusion than normal arteries ( P=0.001), but the extent of hypoperfusion was not different between mild-moderate versus severe stenosis. Multidelay ASL did not perform differently from [15O]-water PET in detecting perfusion abnormalities, but standard ASL overestimated the extent of hypoperfusion in patients ( P=0.003). Conclusions- This simultaneous PET/MRI study supports the use of multidelay ASL MRI in clinical evaluation of Moyamoya disease in settings where nuclear medicine imaging is not available and application of a normative perfusion database to automatically identify abnormal CBF in patients.

Entities:  

Keywords:  Moyamoya disease; cerebral blood flow; magnetic resonance imaging; positron emission tomography

Mesh:

Substances:

Year:  2019        PMID: 30636572     DOI: 10.1161/STROKEAHA.118.023426

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Recurrent transient ischemic attacks in a moyamoya syndrome patient with ultra-long imaging follow-up.

Authors:  Lan Zhang; Wei Xing; Jiajia Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-03

2.  Using arterial spin labeling to measure cerebrovascular reactivity in Moyamoya disease: Insights from simultaneous PET/MRI.

Authors:  Moss Y Zhao; Audrey P Fan; David Yen-Ting Chen; Yosuke Ishii; Mohammad Mehdi Khalighi; Michael Moseley; Gary K Steinberg; Greg Zaharchuk
Journal:  J Cereb Blood Flow Metab       Date:  2022-03-02       Impact factor: 6.960

3.  Diagnostic Accuracy of Screening Arterial Spin-Labeling MRI Using Hadamard Encoding for the Detection of Reduced CBF in Adult Patients with Ischemic Moyamoya Disease.

Authors:  K Setta; T Matsuda; M Sasaki; T Chiba; S Fujiwara; M Kobayashi; K Yoshida; Y Kubo; M Suzuki; K Yoshioka; K Ogasawara
Journal:  AJNR Am J Neuroradiol       Date:  2021-05-20       Impact factor: 4.966

Review 4.  Imaging Transcranial Direct Current Stimulation (tDCS) with Positron Emission Tomography (PET).

Authors:  Thorsten Rudroff; Craig D Workman; Alexandra C Fietsam; Laura L Boles Ponto
Journal:  Brain Sci       Date:  2020-04-15

5.  Concordance of regional hypoperfusion by pCASL MRI and 15O-water PET in frontotemporal dementia: Is pCASL an efficacious alternative?

Authors:  Tracy Ssali; Lucas Narciso; Justin Hicks; Linshan Liu; Sarah Jesso; Lauryn Richardson; Matthias Günther; Simon Konstandin; Klaus Eickel; Frank Prato; Udunna C Anazodo; Elizabeth Finger; Keith St Lawrence
Journal:  Neuroimage Clin       Date:  2022-01-31       Impact factor: 4.881

6.  Reliability of arterial spin labeling derived cerebral blood flow in periventricular white matter.

Authors:  Sudipto Dolui; Audrey P Fan; Moss Y Zhao; Ilya M Nasrallah; Greg Zaharchuk; John A Detre
Journal:  Neuroimage Rep       Date:  2021-11-05

7.  Arterial Spin Labeling Imaging Characteristics of Anti-leucine-rich Glioma-Inactivated 1 Encephalitis: A Qualitative and Quantitative Analysis.

Authors:  Vivek Srikar Yedavalli; Omar Hamam; Mona Bahouth; Victor Cruz Urrutia; Amara Ahmed; Hanzhang Lu; Craig Jones; Licia Pacheco Luna; Haris Iqbal Sair; Bryan Lanzman
Journal:  Front Neurol       Date:  2022-07-28       Impact factor: 4.086

8.  Cerebrovascular Reservoir and Arterial Transit Time Changes Assessed by Acetazolamide-Challenged Multi-Phase Arterial Spin Labeling Perfusion MRI in Chronic Cerebrovascular Steno-Occlusive Disease.

Authors:  Inpyeong Hwang; Chul-Ho Sohn; Keun-Hwa Jung; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Seung Hong Choi; Ji-Hoon Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-01-29

9.  Contralateral improvement of cerebrovascular reactivity and TIA frequency after unilateral revascularization surgery in moyamoya vasculopathy.

Authors:  Pieter T Deckers; Wytse van Hoek; Annick Kronenburg; Maqsood Yaqub; Jeroen C W Siero; Alex A Bhogal; Bart N M van Berckel; Albert van der Zwan; Kees P J Braun
Journal:  Neuroimage Clin       Date:  2021-04-21       Impact factor: 4.881

Review 10.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.